Business
Oxford Nanopore's LamPORE test gains CE-IVD mark
Oxford Nanopore's LamPORE test gains CE-IVD mark.
About this update from Ip Group Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 6442B\n IP Group PLC\n 09 October 2020\n \n \n \n \n \n \n \n FOR RELEASE ON\n \n \n \n \n 9 October 2020\n \n \n \n \n \n \n \n \n THIS ANNOUNCEMENT CONSTITUTES INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO.596/2014.\n \n \n \n \n \n Portfolio company Oxford Nanopore Technologies announces LamPORE test, for the detection of SARS-CoV-2, gains CE-IVD mark with initial roll out in Europe and the UAE\n \n \n \n \n \n IP Group plc (LSE: IPO) (\"IP Group\" or \"the Group\"), the developer of intellectual property-based businesses, notes that its portfolio company Oxford Nanopore Technologies Ltd (\"Oxford Nanopore\" or \"the Company\") has announced that its LamPORE test is now CE marked for in vitro diagnostic use for the detection of the SARS-CoV-2 virus that causes COVID-19, using its GridION device.\n \n \n \n \n \n Oxford Nanopore noted that the LamPORE test is now in the process of initial rollouts in the UK, Germany, Switzerland and the United Arab Emirates. The Company previously announced that it had partnered with the UK's Department of Health and Social Care with an initial order of 450,000 LamPORE SARS-CoV-2 tests and the potential to increase to millions of tests per month. Further regulatory approvals are being pursued in other countries, including Emergency Use Authorisation in the United States, and with its partner G42 in the United Arab Emirates.\n \n \n \n \n \n Oxford Nanopore's LamPORE test has been found to show a sensitivity of 99.1% [96.9-99.9] and specificity of 99.6% [98.0-100] after scientists from the University of Oxford's Nuffield Department of Medicine, Public Health England Porton Down (PHE) and the University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust published their evaluation. The results indicate that LamPORE has a similar performance to RT-PCR for the diagnosis of SARS-CoV-2 infection in symptomatic patients.\n \n \n \n \n \n Alan Aubrey, Chief Executive of IP Group, said: \"Oxford Nanopore has made exceptional technical progress this year while playing a critical role to help support the response to the pandemic. The team at Oxford Nanopore has done an incredible job of bringing this innovative testing platform to market in such a short space of time. Oxford Nanopore is a grea...